Avalyn Pharma Inc. (AVLN)
Nasdaq: AVLN · Pharmaceutical Preparations · filing with the SEC since 2012
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal quarter | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|
| Period ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 |
| Report filed | Nov 12, 2026 | Aug 12, 2026 | Jun 3, 2026 |
| For lenders | |||
| Interest and dividend income | 3,756 | 2,696 | 1,125 |
| Interest and investment income | 2,700 | 2,500 | 900 |
| Research and development | 25,491 | 24,729 | 22,889 |
| General and administrative | 7,603 | 6,561 | 5,020 |
| Total operating expenses | 33,094 | 31,290 | 27,909 |
| Operating income | -33,094 | -31,290 | -27,909 |
| Interest expense | 277 | 272 | 98 |
| Other income (expense), net | -40 | -69 | 13 |
| Total non-operating income (expense) | 3,439 | 2,355 | 1,040 |
| Income tax expense | · | · | 0 |
| Net income including non-controlling interests | · | · | -26,869 |
| Net income | -29,655 | -28,935 | -26,869 |
| Net income to common shareholders | -29,655 | -28,935 | -26,869 |
| Earnings per share, basic | -0.67 | -0.98 | -21.83 |
| Earnings per share, diluted | -0.67 | -0.98 | -21.83 |
| Weighted average shares, basic | 44,354,555 | 29,650,660 | 1,230,698 |
| Weighted average shares, diluted | 44,354,555 | 29,650,660 | 1,230,698 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Each quarter is three months. A fourth quarter prints only where the company tagged its three months on their own; the whole year is in the annual view.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Interest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InterestIncomeOtherResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding